

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>				Complete if Known		
				Application Number	09/847,945	
				Filing Date	May 2, 2001	
				First Named Inventor	Neil P. DESAI	
				Art Unit	1611	
				Examiner Name	L. Channavajjala	
Sheet	1	of	2	Attorney Docket Number		638772000127

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1.	US-2009/0304805-A1	12-10-2009	Desai et al.	
	2.	US-2010/0035800-A1	02-11-2010	Desai et al.	
	3.	US-2010/0112077-A1	05-06-2010	Desai et al.	
	4.	US-2010/0183728-A1	07-22-2010	Desai et al.	
	5.	US-2010/0166869-A1	07-01-2010	Desai et al.	
	6.	US-2010/0215751-A1	08-26-2010	Desai et al.	
	7.	US-6,146,663-A	11-14-2000	Bissery et al.	
	8.	US-6,239,124-B1	05-29-2001	Zenke et al.	
	9.	US-6,268,390-B1	07-31-2001	Kunz	
	10.	US-7,238,369-B2	07-03-2007	McDonald et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
	11.	WO-87/04592-A1	08-13-1987	Liposome Technology, Inc.	
	12.	WO-96/25176-A1	08-22-1996	NeoRx Corporation	
	13.	WO 96/41236-A1	12-19-1996	The Regents of the University of California	
	14.	WO-97/33552-A1	09-18-1997	Wallace Technologies, Inc.	
	15.	WO-97/45105-A1	12-04-1997	Angiotech Pharmaceuticals, Inc.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			²
	16.	BOLLAG, D.M. et al. (June 1, 1995). "Epothilones, a New Class of Microtubule-stabilizing Agents with Taxol-like Mechanisms of Action," <i>Cancer Res.</i> 55:2325-2333.			
	17.	DRACHMAN, D. E. et al. (December 2000). "Neointimal Thickening After Stent Delivery of Paclitaxel: Change in Composition and Arrest of Growth over Six Months," <i>J. Am. Coll. Cardiol.</i> 36(7):2325-2332.			

Substitute for form 1449/PTO				Complete if Known	
				Application Number	09/847,945
				Filing Date	May 2, 2001
				First Named Inventor	Neil P. DESAI
				Art Unit	1611
				Examiner Name	L. Channavajjala
Sheet	2	of	2	Attorney Docket Number	
638772000127					

	18.	MOSELEY, M.E. et al. (October 1991). "Microbubbles: A Novel MR Susceptibility Contrast Agent," <i>10th Annual Meeting of Society of Magnetic Resonance in Medicine, San Francisco, CA.</i> one page.	
	19.	NERI, R. O. et al. (June 1975). "Biological Aspects of Antiandrogens," <i>J. Steroid Biochem.</i> 6(6):815-819.	
	20.	RON, N. et al. (April 2008). "Comparison of Physicochemical Characteristics and Stability of Three Novel Formulations of Paclitaxel: Abraxane, Nanoxel, and Genexol PM," Abstract No. 5622, <i>presented at 99th AACR Annual Meeting</i> , San Diego, CA, April 12-16, 2008, located at < http://www.aacrmeetingabstracts.org/cgi/content/meeting_abstract/2008/1_Annual_Meeting/5622?maxtoshow=&hits=10&RESULTFORMAT=1&author1=ron&andorexacttitle=and&andorexacttitleabs=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&fdate=1/1/2004&tdate=12/31/2009&resourcetype=HWCIT >, last visited on September 30, 2010, 2 pages.	
	21.	VERRECCHIA, T. et al. (September 1995). "Non-Stealth (Poly (Lactic Acid/Albumin)) and Stealth (Poly (Lactic Acid-Polyethylene Glycol)) Nanoparticles as Injectable Drug Carriers," <i>J. Controlled Release</i> 36:49-61.	
	22.	KARANIAN, J. W. et al. (October 2010). "Efficiency of Drug Delivery to the Coronary Arteries in Swine is Dependent on the Route of Administration: Assessment of Luminai, Intimal, and Adventitial Coronary Artery and Venous Delivery Methods," <i>J. Vasc. Interv. Radiol.</i> 21:1555-1564.	
	23.	MARGOLIS, J. et al. (April 2007). "Systemic Nanoparticle Paclitaxel (<i>nab</i> -Paclitaxel) for In-Stent Restenosis I (SNAPIST-I): A First-in-Human Safety and Dose-Finding Study," <i>Clin. Cardiol.</i> 30:165-170.	
	24.	U.S. Patent Application No. 12/713,092 filed on February 25, 2010, for Desai et al. (copy not attached).	
	25.	U.S. Patent Application No. 12/761,292 filed on April 15, 2010 for Desai et al. (copy not attached).	
	26.	U.S. Patent Application No. 12/818,099 filed on June 17, 2010, for De et al. (copy not attached).	
	27.	U.S. Patent Application No. 12/824,014 filed on June 25, 2010 for Desai et al. (copy not attached).	
	28.	U.S. Patent Application No. 12/832,876 filed on July 8, 2010, for Desai et al. (copy not attached).	
	29.	U.S. Patent Application No. 12/874,965 filed on September 2, 2010 for De et al. (copy not attached).	
	30.	U.S. Patent Application No. 12/690,693, filed October 22, 2010, for Desai et al. (copy not attached).	

Examiner Signature	/Lakshmi Channavajjala/	Date Considered	03/10/2011
--------------------	-------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.C./